Crittenden M - Search Results

1

Targeting MerTK Enhances Adaptive Immune Responses After Radiation Therapy.

Tormoen GW, Blair TC, Bambina S, Kramer G, Baird J, Rahmani R, Holland JM, McCarty OJT, Baine MJ, Verma V, Nabavizadeh N, Gough MJ, Crittenden M. Tormoen GW, et al. Among authors: crittenden m. Int J Radiat Oncol Biol Phys. 2020 Sep 1;108(1):93-103. doi: 10.1016/j.ijrobp.2020.04.013. Epub 2020 Apr 18. Int J Radiat Oncol Biol Phys. 2020. PMID: 32311417 Free PMC article.

2

Macrophages orchestrate the immune response to tumor cell death.

Gough MJ, Melcher AA, Ahmed A, Crittenden MR, Riddle DS, Linardakis E, Ruchatz AN, Emiliusen LM, Vile RG. Gough MJ, et al. Among authors: crittenden mr. Cancer Res. 2001 Oct 1;61(19):7240-7. Cancer Res. 2001. PMID: 11585761

3

Tumor antigen-specific induction of transcriptionally targeted retroviral vectors from chimeric immune receptor-modified T cells.

Chester J, Ruchatz A, Gough M, Crittenden M, Chong H, Cosset FL, Diaz RM, Harrington K, Alvarez-Vallina L, Vile R. Chester J, et al. Among authors: crittenden m. Nat Biotechnol. 2002 Mar;20(3):256-63. doi: 10.1038/nbt0302-256. Nat Biotechnol. 2002. PMID: 11875426

4

Pharmacologically regulated production of targeted retrovirus from T cells for systemic antitumor gene therapy.

Crittenden M, Gough M, Chester J, Kottke T, Thompson J, Ruchatz A, Clackson T, Cosset FL, Chong H, Diaz RM, Harrington K, Alvarez Vallina L, Vile R. Crittenden M, et al. Cancer Res. 2003 Jun 15;63(12):3173-80. Cancer Res. 2003. PMID: 12810645

5

Expression of inflammatory chemokines combined with local tumor destruction enhances tumor regression and long-term immunity.

Crittenden M, Gough M, Harrington K, Olivier K, Thompson J, Vile RG. Crittenden M, et al. Cancer Res. 2003 Sep 1;63(17):5505-12. Cancer Res. 2003. PMID: 14500387

6

Induction of cell stress through gene transfer of an engineered heat shock transcription factor enhances tumor immunogenicity.

Gough MJ, Melcher AA, Crittenden MR, Sanchez-Perez L, Voellmy R, Vile RG. Gough MJ, et al. Among authors: crittenden mr. Gene Ther. 2004 Jul;11(13):1099-104. doi: 10.1038/sj.gt.3302274. Gene Ther. 2004. PMID: 15103319

7

MIP-3alpha transfection into a rodent tumor cell line increases intratumoral dendritic cell infiltration but enhances (facilitates) tumor growth and decreases immunogenicity.

Bonnotte B, Crittenden M, Larmonier N, Gough M, Vile RG. Bonnotte B, et al. Among authors: crittenden m. J Immunol. 2004 Oct 15;173(8):4929-35. doi: 10.4049/jimmunol.173.8.4929. J Immunol. 2004. PMID: 15470034

8

Intratumoral immunotherapy: using the tumour against itself.

Crittenden MR, Thanarajasingam U, Vile RG, Gough MJ. Crittenden MR, et al. Immunology. 2005 Jan;114(1):11-22. doi: 10.1111/j.1365-2567.2004.02001.x. Immunology. 2005. PMID: 15606790 Free PMC article. Review.

9

Gene therapy to manipulate effector T cell trafficking to tumors for immunotherapy.

Gough M, Crittenden M, Thanarajasingam U, Sanchez-Perez L, Thompson J, Jevremovic D, Vile R. Gough M, et al. Among authors: crittenden m. J Immunol. 2005 May 1;174(9):5766-73. doi: 10.4049/jimmunol.174.9.5766. J Immunol. 2005. PMID: 15843579

10

Combination approaches to immunotherapy: the radiotherapy example.

Gough MJ, Crittenden MR. Gough MJ, et al. Immunotherapy. 2009 Nov;1(6):1025-37. doi: 10.2217/imt.09.64. Immunotherapy. 2009. PMID: 20635917 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

137 results

Search Page